-
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial
Study
EGAS50000001572
-
Discovery and validation of an ancillary genomic test of malignancy for primary melanocytic tumors
Study
EGAS50000000887
-
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Study
EGAS50000000710
-
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Study
EGAS00001000226
-
Proteom characterization in primary colorectal cancer and corresponding liver metastasis
Study
EGAS00001005641
-
Biomarker Screen for Efficacy of Oncolytic Virotherapy in Patient-derived Pancreatic Cancer Cultures
Study
EGAS00001007001
-
MethylationEPIC BeadChip samples of pre- and post-5ZA-treated head and neck cancer patients refractory to anto-PD-1 therapy
Study
EGAS00001007998
-
Study of Melanoma Risk in Australia and the United Kingdom
Study
phs000519
-
Natural Killer Cell Therapies for Hematologic Malignancies
Study
phs002681
-
Circulating kidney injury molecule-1 (KIM-1) and association with response to adjuvant immunotherapy in renal cell carcinoma
Study
EGAS50000001285
-
Next-Generation Sequencing of RNA and DNA Isolated from Paired Fresh-Frozen and Formalin-Fixed Paraffin-Embedded Samples of Human Cancer and Normal Tissue
Study
EGAS00001000737
-
Successful immune checkpoint blockade in a patient with advanced stage microsatellite unstable biliary tract cancer (H021)
Study
EGAS00001002441
-
B cell receptor silencing reveals origin and dependencies of high-grade B cell lymphomas with MYC and BCL2 rearrangements
Study
EGAS50000001047
-
HCA_Thymus_Disease_DiGeorge_Transplant_RNA
Study
EGAS00001004025
-
Lindsey E. Jones et al. Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma. Neuro-Oncology Advances, 2020. We established robust, versatile, and well-characterized Patient Derived Cells (PDC) of an IDH1-mutant astrocytoma and an IDH1-mutant oligodendroglioma that represents defined evolutionary stages of chemotherapy-induced hypermutation. The PDCs retain tumor subtype defining features over time as well as classic hallmarks of cancer, including anchorage independent growth and cell immortality. The integrated phylogenies composed of PDCs,single-cell-derived PDCs, patient-derived xenografts, and corresponding spatiotemporal tumor tissue samples also provide new insight into the clonality, evolutionary pattern, and immense mutational load of hypermutated IDH mutant gliomas.
Study
EGAS00001003992
-
eMERGE Network Phase III: HRC SNV and 1000 Genomes SV Imputed Array Data of 105,000 Participants
Study
phs001584
-
Research Program on Genes, Environment and Health (RPGEH)
Study
phs000788
-
The Genetic Architecture of Smoking and Smoking Cessation
Study
phs000404
-
MediMer: A versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection
Study
EGAS50000000065
-
Institut Curie Neuroblastoma Whole Genome Sequencing Diagnosis Relapse
Study
EGAS00001001184
-
Study of Addiction: Genetics and Environment (SAGE)
Study
phs000092
-
Development and Use of Network Infrastructure for High-Throughput GWA Studies
Study
phs000234